Although the development of treatments for spinal cord injuries (SCI) is progressing,
effective cure has not yet been established. This is not only an issue for Japan
but it is also global. Anticipation grows for regenerative medicine (and its study)
as a vital therapeutic tool for SCI and cerebral infarctions.
The research groups of Professor Hideyuki Okano, Department of Physiology,
Keio University School of Medicine, and Professor Masaya Nakamura,
Department of Orthopedic Surgery, have discovered a differentiation-inducing method for iPSC to neural progenitor cells and have strived to apply this in the treatment of SCI.
In addition, we have focused on elucidating pathological conditions and drug discovery research for intractable neurological diseases utilizing diseases-model iPS cell technology.
K Pharma, Inc. was established for the purpose of implementing these research subjects.
As a spin off venture from Keio University, we are committed to the practical application
of nerve regeneration technology and the development of effective drug discovery for intractable neurological diseases.
We dedicate ourselves to contributing to the society in the medical field through early implementation of neuro-regenerative technology as well as drug development and industrialization, for intractable neurological diseases.